10-K: DT Cloud Acquisition Corporation Files 10-K Report, Details Business Combination with Maius Pharmaceutical

DT Cloud Acquisition Corporation files its annual report on Form 10-K, outlining its business activities and the proposed business combination with Maius Pharmaceutical.

Summary

• DT Cloud Acquisition Corporation, a blank check company, filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company was formed to effect a business combination with one or more businesses.
• On February 23, 2024, DT Cloud consummated its initial public offering (IPO), generating gross proceeds of $69 million.
• Simultaneously with the IPO, the company consummated a private placement with its sponsor, DT Cloud Capital Corp., generating gross proceeds of $2.345 million.
• As of February 23, 2024, $69.345 million of the net proceeds from the IPO and private placement were deposited in a trust account.
• On October 22, 2024, DT Cloud entered into a business combination agreement with Maius Pharmaceutical Co., Ltd.
• The business combination is subject to certain closing conditions, including shareholder approvals and effectiveness of a registration statement.
• The Sponsor has agreed to vote in favor of the Business Combination.
• The Sponsor has caused the first monthly extension fee of US$207,000 (equivalent to US$0.03 per outstanding public share) to be deposited into the Trust Account on February 22, 2025, extending the latest time for completion of initial business combination from February 23, 2025 by an additional one (1) month.
• On March 25, 2025, the Company deposited $150,949 into the Trust Account in order to extend the amount of available time to complete a business combination until April 23, 2025.
• As such, as of the date of this Report, the deadline for completing of an initial business combination was extended to April 23, 2025.
• The company reported a net income of $2,265,806 for the year ended December 31, 2024.
• The report includes a discussion of risk factors associated with an investment in the company's securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is pursuing a business combination and has extended its deadline, there are also significant risks and uncertainties associated with the transaction.

Positives

• The company has secured funding through its IPO and private placement.
• The company is actively pursuing a business combination with Maius Pharmaceutical.
• The deadline for completing the initial business combination has been extended, providing more time to finalize the transaction.
• The company reported a net income of $2,265,806 for the year ended December 31, 2024.

Negatives

• The company is a blank check company with no operating history.
• The business combination is subject to various closing conditions and may not be completed.
• The company may be unable to obtain additional financing, if required, to complete the business combination.
• The company's independent registered public accounting firms report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern.

Risks

• The company may be unable to consummate a business combination.
• The company may not have sufficient funds to consummate the business combination.
• The company may be unable to obtain additional financing, if required, to complete the business combination.
• The company may be subject to U.S. foreign investment regulations and review by a U.S. government entity.
• The company may effect a business combination with a company located outside of the United States and if we do, we would be subject to a variety of additional risks that may negatively impact our business operations and financial results.
• Given the PRC government's potential oversight and discretion over the conduct of our directors and officers search for a target company, the PRC government may intervene or influence our operations at any time, which could result in a material change in our search for a target business and/or the value of the securities we are registering.
• Changes in the policies, regulations, rules, and the enforcement of laws of the PRC may be adopted quickly with little advance notice and could have a significant impact upon our ability to operate.
• The PRC government has indicated its intent to intervene in or influence a PRC company's business operations at any time or to exert more oversight and control over offerings conducted overseas and foreign investment in China-based issuers.
• The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into our initial business combination with a target.

Future Outlook

The company intends to complete a business combination, but there is no assurance that it will be successful.

Industry Context

The announcement is typical for special purpose acquisition companies (SPACs) that are nearing their deadline to complete a business combination.

Comparison to Industry Standards

• The financial metrics and timelines are generally consistent with other SPACs.
• Comparable companies include other SPACs seeking acquisitions in the pharmaceutical or healthcare sectors.
• The success of the business combination will depend on the performance of Maius Pharmaceutical and its ability to meet industry benchmarks.

Related Party Transactions

• The company pays an affiliate of its sponsor $10,000 per month for administrative support services.
• The sponsor may provide working capital loans to the company.

Stakeholder Impact

• Shareholders may experience dilution if additional shares are issued to complete the business combination.
• The success of the business combination will impact the value of the company's securities.
• Employees of the target business may be affected by the transaction.

Next Steps

• Obtain shareholder approvals for the business combination.
• Satisfy all closing conditions outlined in the business combination agreement.
• Secure additional financing, if required, to complete the transaction.

Key Dates

Keywords

business combination, acquisition, SPAC, Maius Pharmaceutical, blank check company, IPO, trust account, redemption, sponsor, financials